Tevogen Bio Holdings Inc. announced that it had expanded its relations with Microsoft Corporation in order to extend its IA -focused collaboration and develop its predictcell technology. PREDICTCELL is the owner of Tevogen BIO designed for the predictive targeting of precision T cells. This enlarged relationship is designed to exploit Microsoft’s advanced AI, Cloud and Microsoft expertise in the health and life sciences in order to accelerate the identification of targets and preclinical processes of Tevogen Bio, thus strengthening the company’s innovative immunotherapy pipeline.
Tevogen.ai, the effort of Tevogen organic in artificial intelligence, will integrate the advanced artificial intelligence tools of Microsoft and the Cloud Microsoft Azure platform in two key objectives: quickly develop the preclinical pipeline of the Exactcell technology? Technology Pre-Clinical Pipeline: Drawing on the positive results of the TVGN 489, Tevogen Bio test aims to use automatic learning to perform critical simulations that will accelerate the identification of new targets. By relying on Microsoft’s AI, the company can analyze large sets of data on the genome with increased speed and precision.
Development of proprietary algorithms to decode the interactions between HLA-T: Tevogen.ai, in collaboration with Microsoft experts, will create new algorithms to decode interactions between human leukocyte antigens (HLA) and T cells. This capacity should make it possible to significantly improve the treatment capacities of T cells. This capacity should allow Tevogen Bio to considerably improve its understanding of immune responses and to open new therapeutic paths, in particular in the fields where data existing are minimal. By taking advantage of the Microsoft Azure platform and a series of advanced AI tools, Tevogen Bio also proactively studies potential treatments for the human papillom virus (HPV).
The company has developed a set of data on HPV genome proteins and identifies cytotoxic T cell targets (CTL) to be selected for a clinical trial for TVGN 920, the first candidate product of Tevogen in oncology. Thanks to the Exactcell exclusive technology? of the company, which consists in causing CTLs to detect specific targets and developing them, Tevogen aims to be ready to provide CTL treatment specific to HPV.
